Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Market Cap	8.94B +5.3%
Revenue (ttm)	15.96B -1.5%
Net Income	309.80M -53.4%
EPS	0.12 -54.1%
Shares Out	2.52B
PE Ratio	29.67
Forward PE	19.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,891,617
Average Volume	140,747,153
Open	3.530
Previous Close	3.550
Day's Range	3.440 - 3.530
52-Week Range	3.200 - 4.880
Beta	0.16
RSI	39.58
Earnings Date	Apr 23, 2026

About SHA:600664

Harbin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and trade of pharmaceuticals in China and internationally. The company operates through seven segments: Antibiotics, Small-Molecular Drug Preparations, OTC and Healthcare Products, Modern Chinese Medicines, Biopharmaceuticals, Animal Vaccines, and Medicine Circulations. It offers a series of penicillin and cephalosporin products, as well as intermediates. The company's lead products include Shuang Huanglian freeze-dried injection; Danshen freeze-dried injec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 10,180
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600664

Financial Performance

In 2025, SHA:600664's revenue was 15.96 billion, a decrease of -1.31% compared to the previous year's 16.18 billion. Earnings were 361.60 million, a decrease of -42.50%.